GlassScriptPhysician profile
James B Vogt
NPI 1740332352
$3,227.53
in general payments reported to CMS, 2019-2025
23 companies · $80.60 in 2025
The $80.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $22.36 · 2021: $455 · 2022: $1,197 · 2023: $1,098 · 2024: $109 · 2025: $80.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,027.25 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $703.87 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $276.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.05 | 2022-2023 | |
| Glaxosmithkline, LLC. | $144.70 | 2019-2022 | |
| Abbott Laboratories | $136.69 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $87.62 | 2022-2023 | Quviviq |
| Medtronic, INC. | $83.01 | 2022-2023 | Inpen Smart Insulin Delivery System, Minimed 780g, Minimed 770g |
| Medtronic USA, INC. | $81.82 | 2019 | |
| Pfizer INC. | $77.22 | 2022-2023 | |
| Corcept Therapeutics | $63.54 | 2021-2022 | |
| Almatica Pharma LLC | $62.02 | 2022-2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Novo Nordisk INC | $56.04 | 2022-2024 | Wegovy |
| Intuity Medical INC | $38.42 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Avanir Pharmaceuticals, INC. | $34.55 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.09 | 2022-2025 | Repatha |
| Astellas Pharma US INC | $22.36 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.44 | 2022 | |
| Optinose US, INC. | $19.03 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.24 | 2022 | |
| Cequr Corporation | $16.81 | 2023 | Cequr Simplicity |
| Surgenex LLC | $15.81 | 2025 | Surgraft, Surmatrix, Pellograft |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Vogt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.